-
Fiche maladie | 2021.07.22
Lyme disease (Lyme borreliosis)
Lyme disease, also known as Lyme borreliosis, is a tick-borne disease. It is the most widespread vector-borne disease in the entire northern hemisphere. Its incidence continues to rise at global level as a result of demographic and environmental factors, including climate change.
-
News | 2022.07.09
Conversation: capacity building to prepare for the future
Institut Pasteur Senior Executive Scientific Vice-President Christophe d'Enfert provides a brief, cross-disciplinary overview of 2021 covering capacity building, enhanced partnerships and future technologies.
-
News | 2024.12.16
Microbiota tailored skin humoral immunity and its potential for the development of novel vaccinal approaches
Scientists have just made two major discoveries about a harmless bacterium, Staphylococcus epidermidis, present on our skin. A first study identifies the skin as a compartment able to develop highly protective antibody responses to skin colonizing microbe in the absence of inflammation or lymph node contribution. A second study concerns the development of a topical vaccine that can be applied...
-
Article | 2023.12.18
Interdisciplinary Training in Genomic Epidemiology and Public Health Bioinformatics
This interdisciplinary programme, funded by ECDC, combines lectures and practical sessions delivered by multiple host institutions in order to enhance surveillance, preparedness, and readiness to respond to outbreaks.
-
News | 2025.07.15
Training minds, advancing science: the Institut Pasteur strengthens its philanthropic program for education
Since its founding, the Institut Pasteur has been committed to training scientists and health professionals who address major global health challenges. Today, in a rapidly evolving world, this commitment enters a new phase with the launch of a structured program to support education, aimed at strengthening access, quality, and impact of the scientific training provided by the Institut Pasteur.
-
Fiche maladie | 2019.10.16
Chikungunya
Chikungunya is a viral disease transmitted to humans by the bite of Aedes albopictus and Aedes aegypti mosquitoes. Although rarely fatal, chikungunya can cause significant pain and debilitating symptoms that affect patients' quality of life. Existing treatments are solely symptomatic. In France, the current conditions in 80% of départements are conducive to the emergence of chikungunya.
-
Document de presse | 2023.02.20
HIV: third case in the world of probable cure after a bone marrow transplant
Forty years after the discovery of HIV in 1983 at the Institut Pasteur, 38.4 million people were living with the virus worldwide in 2021.[1] Only two cases of people being cured had previously been described: the Berlin patient in 2009 and the London patient in 2019. The IciStem consortium, whose members include Asier Sáez-Cirión's team at the Institut Pasteur, in collaboration with Düsseldorf...
-
Document de presse | 2023.03.29
World Autism Awareness Day: Institut Pasteur working actively with clinicians and the autism community
As we mark World Autism Awareness Day on Sunday April 2, 2023, this year the Institut Pasteur is celebrating the 20th anniversary of the discovery of the first genes associated with autism. In 2003, this discovery offered a new perspective on the neurodevelopmental disorder; today, it highlights what still needs to be done to help those affected by autism. Scientists in international consortia...
-
News | 2024.07.30
Paris 2024: ready, set, go for the Institut Pasteur's volunteers involved in the Games!
Throughout this special Paris Games, we are pleased to present some of the Institut Pasteur staff who are playing a special role in this global event – whether in their capacity as an Institut Pasteur staff member, a volunteer or a sports person. We hope that these profiles will showcase the fantastic diversity of the Institut Pasteur community. This week, to mark the official opening of the...
-
Document de presse | 2014.09.09
Highly regulated therapeutic target shows promise in the search for new antimalarial treatments
Artemisinin is currently the most effective malarial treatment available. However, the recent emergence in South-East Asia of artemisinin-resistant parasites strengthens the urgent need to identify a new generation of antimalarial drugs. In this context, scientists at the Institut Pasteur and CNRS have determined the three-dimensional structure of a promising new therapeutic target for malaria:...